Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Gabriele Luppi, Amr S. Saad et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 61
Unusual Selection of Rta181V Hbv Mutants Cross-Resistant to Adefovir following Prolonged Lamivudine Monotherapy: Report of Two CasesRené Gerolami, Catherine Tamalet, Marc Bourlière et al.|Antiviral Therapy|2006Cited by 26
Fulminant Hepatitis B Associated with a Specific Insertion in the Basal Core Promoter Region of Hepatitis B Virus DNA after Immunosuppressive TreatmentRené Gerolami, Catherine Tamalet, Patrick Borentain et al.|Clinical Infectious Diseases|2005Cited by 23
451 High prevalence of hepatitis B virus infection in B-cell non-hodgkin lymphomaPatrick Borentain, René Gerolami, Philippe Colson et al.|Journal of Hepatology|2006Cited by 3
P.101 Unusual selection of rta181V HBV mutants cross-resistant to adefovir under lamivudine monotherapy: report of two casesRené Gerolami, Catherine Tamalet, Marc Bourlière et al.|Journal of Clinical Virology|2006Cited by 1